4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
4.640
-0.030 (-0.64%)
At close: Feb 21, 2025, 4:00 PM
4.870
+0.230 (4.96%)
After-hours: Feb 21, 2025, 5:44 PM EST
4D Molecular Therapeutics Revenue
4D Molecular Therapeutics had revenue of $3.00K in the quarter ending September 30, 2024, a decrease of -99.99%. This brings the company's revenue in the last twelve months to $17.00K, down -99.92% year-over-year. In the year 2023, 4D Molecular Therapeutics had annual revenue of $20.72M with 562.29% growth.
Revenue (ttm)
$17.00K
Revenue Growth
-99.92%
P/S Ratio
12,617.45
Revenue / Employee
$116
Employees
147
Market Cap
214.50M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
FDMT News
- 3 days ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 days ago - 4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression - Seeking Alpha
- 12 days ago - Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study - Benzinga
- 13 days ago - 4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program - GlobeNewsWire
- 3 months ago - 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire
- 3 months ago - 4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation - Accesswire
- 4 months ago - 4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out - Accesswire
- 4 months ago - 4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out - Accesswire